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OBJECTIVES The aim of this study was to determine the long-term prognosis with postoperative markers
of myocardial ischemia and infarction.
BACKGROUND Cardiac troponins (cTn) are superior to creatine kinase-MB fraction (CK-MB) in detecting
perioperative myocardial infarction (PMI). However, their threshold levels signifying PMI
and their long-term prognostic value are not yet determined.
METHODS A cohort of 447 consecutive patients who underwent 501 major vascular procedures was
prospectively studied. Perioperative continuous 12-lead electrocardiogram monitoring, car-
diac troponin-I (cTn-I) and/or cardiac troponin-T (cTn-T), and CK-MB levels on the first
three postoperative days, and long-term survival were determined. The association of different
cutoff levels of CK-MB, troponin, and ischemia duration with long-term survival was
investigated.
RESULTS Between 14 (2.9%) and 107 (23.9%) of the patients sustained PMI, depending on the
biochemical criteria used. Elevated postoperative CK-MB, cTn, and prolonged (30 min)
ischemia, at all cutoff levels examined, predicted long-term mortality independent of the
preoperative predictors: patient’s age, type of vascular surgery, previous myocardial infarction,
and renal failure (Cox multivariate analysis). Both CK-MB 10% and cTn-I 1.5 ng/ml
and/or cTn-T 0.1 ng/ml independently predicted a 3.75-fold and 2.06-fold increase in
long-term mortality (p  0.006 and 0.012, respectively). Similarly, both CK-MB 5% and
cTn-I 0.6 ng/ml and/or cTn-T 0.03 ng/ml independently predicted a 2.15-fold and
1.89-fold increase in mortality (p  0.018 and 0.01, respectively). Patients with both these
markers elevated had a 4.19-fold increase in mortality (p  0.001).
CONCLUSIONS Postoperative CK-MB and troponin, even at low cutoff levels, are independent and
complementary predictors of long-term mortality after major vascular surgery. (J Am Coll
Cardiol 2003;42:1547–54) © 2003 by the American College of Cardiology Foundation
Postoperative myocardial infarction (MI) and major cardiac
complications occur in more than 4% of the patients with
either established diagnosis of coronary artery disease
(CAD) or risk factors for CAD, who undergo major
non-cardiac surgery (1,2). In the U.S., 1.5 to 2 million
patients are at such risk for postoperative infarction each
year (3). There is marked variability in the reported short-
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term mortality (10% to 70%) (4–6), and there are very few
data on the long-term prognosis after postoperative infarc-
tion (2,7,8). Unlike non-surgical MI, the clinical diagnosis
of perioperative MI (PMI) is often difficult or even impos-
sible, when based on the presence of two of the classical
triad: cardiac symptoms, typical electrocardiographic
(ECG) findings, and biochemical markers. The silent na-
ture of perioperative infarction, the subtle and transient
ST-depression ECG changes resulting in non–Q-wave
infarction (4), and the claimed low specificity of creatine
kinase-MB fraction (CK-MB) isoenzyme (9) all lead to
inconsistencies in the diagnosis of PMI and to uncertainty
as to the long-term significance of perioperative markers of
MI.
Cardiac troponins (cTn) are highly sensitive and specific
biochemical markers for myocardial necrosis and predict
increased risk of mortality and reinfarction in patients
presenting with acute coronary syndrome (ACS) (10,11).
In surgical patients too, cTn have been shown to identify
postoperative MI better than CK-MB isoenzyme
(4,9,12,13). However, in the absence of typical signs and
symptoms of MI, the diagnosis of postoperative MI has to
rely heavily on the rise and fall of biochemical markers,
especially on cTn (14). It is yet unclear, however, whether
postoperative infarction detected predominantly on the
basis of these markers bears the same clinical and prognostic
implications as non-surgical infarction and, therefore, re-
quires similar surveillance and treatment. Moreover,
whereas in non-surgical patients with unstable coronary
syndromes even the smallest increase in cardiac troponin-I
(cTn-I) or cardiac troponin-T (cTn-T) is associated with
worse outcome (15), there is as of yet no consensus
concerning the threshold levels of cTn signifying postoper-
ative MI, leading researchers to use different concentrations
for its diagnosis.
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The present study aims to determine whether elevated
postoperative troponin levels have significant prognostic
implications and to define the plasma concentrations of
cTn-I and cTn-T and CK-MB that correlate with postop-
erative myocardial ischemia based on continuous 12-lead
ECG monitoring and with long-term survival. This was
prospectively examined in a large cohort of vascular surgery
patients.
METHODS
After approval by the Institutional Review Board and
informed consent, 447 consecutive patients who underwent
501 major vascular surgical procedures (231 carotid endar-
terectomies, 77 abdominal aortic operations, and 193 lower-
extremity bypass procedures) at the Hadassah University
Hospital from July 1997 to June 2001 were studied. The 49
patients who had more than one operation were included
only once in the study. Those with no perioperative cardiac
event or increase in cardiac markers were included on their
first operation. If, however, one of the operations was
complicated by a cardiac event or an increase in a cardiac
marker, only that operation was included. None of the
patients had unstable coronary syndrome in the three
months preceding surgery. All preoperative chronic cardio-
vascular medications, including -blockers and aspirin, were
continued until the day of surgery and resumed as soon as
possible postoperatively. After completion of surgery, pa-
tients were maintained in the recovery room or intensive
care unit until at least the morning after surgery and were
monitored with continuous intra-arterial blood pressure.
The preoperative clinical findings and the perioperative
cardiac complications were recorded prospectively.
Continuous 12-lead ECG recording. Continuous 12-lead
ECG recording has been described previously (4). In brief,
before induction of anesthesia, patients were connected to a
continuous 12-lead ECG monitor (Solar 7000, Marquette
Electronics, Milwaukee, Wisconsin), wired to a Cardiac
Review Station (ST-Guard, Marquette Electronics), which
automatically stored all 12-lead ECG complexes every
minute and measured the absolute and relative ST-segment
deviation at 60 milliseconds after the J point in all leads
compared with their preoperative baseline. Episodes of
ST-segment deviation, defined as ST depression or eleva-
tion of0.2 mV in one lead or0.1 mV in two contiguous
leads that lasted more than 10 min, were automatically
detected and marked by the ST-Guard. ST deviations
lasting 10 min were ignored. Monitoring was continued
for at least 48 h and up to 72 h. All 12-lead ST-segment
trends were reviewed and periods marked by the ST-Guard,
as ST-segment deviations were inspected visually and ST
deviations caused by artifacts or pure up-sloping ST-
segment depression were not considered as ischemia. Each
patient’s longest and cumulative ischemia duration, as well
as the number of ischemic events was recorded.
Biochemical markers of MI. The cTn-I and/or cTn-T
levels and CK-MB were measured in all patients immedi-
ately after surgery and every morning in the first three
postoperative days. If either one of these markers was
elevated, its measurement was continued for the next days
until its return to normal values. Until January 1999 only
troponin-I was available in our institution. From January
1999, cTn-T served as the primary indicator for MI,
whereas cTn-I was used mainly for confirmation in patients
with impaired renal function exhibiting high levels of
troponin-T. Troponin-I was measured using a Stratus II
analyzer (Dade-Behring, Inc., Marburg, Germany) by mass
immunoassay with two monoclonal specific antibodies.
Troponin-T was measured by an electrochemiluminescence
immunoassay on the Elecsys 2010 system (Boehringer
Ingelheim GmbH, Germany).
Biochemical cutoff levels. Three different cutoff levels of
cTn were examined: 1) cTn-I 1.5 ng/ml and/or cTn-T
0.1 ng/ml. These were the receiver operator characteristic
curve medical decision cutoffs for MI defined by the
manufacturers of these assays. 2) cTn-I 0.6 ng/ml and/or
cTn-T 0.03 ng/ml, which correspond to the lowest levels
with 10% imprecision or coefficient of variation for these
assays (16). 3) cTn-I 3.1 ng/ml and/or cTn-T 0.2
ng/ml, which, based on previous studies including ours
(4,5,9,17), showed a better correlation with postoperative
ischemia and infarction.
The CK was measured by a Vitros dry chemistry analyzer
(Ortho Clinical Diagnostics, Johnson & Johnson) using dry
slide technology. The upper limit of normal for CK total
was 170 IU. The upper limit of normal for CK-MB/total
CK in our laboratory was 10%; however, the cutoff level of
5% that is more often used for defining MI (18) was also
investigated.
Clinical cardiac complications. Clinical MI was diag-
nosed by the treating physicians independent of this study,
if cTn-I 1.5 ng/ml and/or cTn-T 0.1 were associated
with at least one of the following: typical ischemic symp-
toms, ECG changes indicative of ischemia, or new patho-
logic Q-waves (12). Prolonged chest pain, signs and symp-
toms of congestive heart failure, and new persistent
arrhythmia were considered attributable to PMI if they were
temporally associated with elevated cardiac markers. Car-
diac death was defined as death secondary to MI, arrhyth-
mia, or congestive heart failure.
Long-term survival. Long-term survival was recorded
from the hospital’s information system, which is constantly
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CAD  coronary artery disease
CK-MB  creatine kinase-MB fraction
cTn  cardiac troponin
ECG  electrocardiogram/electrocardiograph/
electrocardiographic
MI  myocardial infarction
PMI  perioperative myocardial infarction
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updated by the Israeli Ministry of the Interior with all newly
deceased individuals along with the date of their death.
Statistical analyses. Chi-square analyses were used to
compare dichotomous variables between groups of patients.
Kaplan-Meier log-rank test and univariate and multivariate
Cox regression models were used to compare survival
among groups and to define predictors of long-term sur-
vival. All potential preoperative predictors with p  0.1 on
univariate survival analysis were included in the Cox mul-
tivariate regression analysis, and a backward conditional
selection method was used for variable selection by the
model. A value of p  0.05 was considered statistically
significant. All the analyses were performed using SPSS
version 10.0 (SPSS Inc., Chicago, Illinois).
RESULTS
The demographic and preoperative clinical data on the 447
patients are summarized in Table 1.
Myocardial ischemia. During 25,622 patient-hours of
continuous 12-lead ECG monitoring (51.4  15.7 h/pa-
tient), 66 patients had 104 ischemic episodes; all but one
were denoted only by ST-segment depression alone. One
patient had episodes of ST depression in the chest leads
associated with ST elevation in the inferior leads. The
duration of the longest ischemic episode in each patient was
16  62 min (range, 11 to 625 min), and the cumulative
ischemia duration of each patient was 23 101 min (range,
11 to 1,150 min). The longest ischemic episode lasted over
30 min in 44 (9.8%) of the patients and over 60 min in 23
(5.1%) of the patients.
MI. Between 14 (2.9%) and 107 (23.9%) of the patients
sustained postoperative MI, depending on the biochemical
criteria used (Table 2). Only 17.7% to 61.9% of them had
signs or symptoms attributable to infarction. None of the
patients had new Q-waves.
Each of the biochemical criteria for MI was associated
with prolonged postoperative ischemia. The higher levels of
troponin and CK-MB were associated with a higher inci-
dence of prolonged postoperative ischemia (Table 2).
Sixteen (3.6%) patients were diagnosed by the treating
physicians as having postoperative MI, based on the com-
bination of elevated cTn with ECG findings and/or pro-
longed chest pain. Twelve (2.8%) of these patients had
symptoms attributable to MI: five experienced chest pain,
eight had congestive heart failure (one suffered from both).
All 12 patients had both elevated cTn levels and prolonged
(60 min) postoperative ischemia. Two other patients died
shortly after postoperative infarction (8 and 32 days post-
operatively); none of them had typical symptoms of MI, and
the diagnosis was made on the basis of the biochemical
markers and the 12-lead ECG findings. Three additional
patients died postoperatively from non-cardiac causes. All
other patients left the hospital in stable condition.
Long-term survival. During the one- to five-year
follow-up period (mean: 32.3  13.8 months), 82 patients
(18.3%) died. Table 3 summarizes the univariate and
multivariate Cox survival analysis of the preoperative and
postoperative predictors of survival. By multivariate Cox
regression analysis, age, type of vascular surgery (lower-
extremity bypass surgery), previous MI, and renal insuffi-
ciency were the only preoperative predictors of long-term
survival.
All cutoff levels of CK-MB, cTn, and ischemia duration
examined predicted long-term survival by univariate analysis
(Figs. 1 to 3). Similarly, when the multivariate model
included the preoperative predictors in addition to the
Table 1. Preoperative Demographic and Clinical Data
All Patients
(N  447) No. (%)
Age, yrs, mean  SD [range] 68  10 [39–92]
Gender (male/female) 312/135 (69.8/30.2)
Surgery
CEA 214 (47.9)
AAA 70 (15.7)
Infra-inguinal BP 163 (36.5)
Diabetes mellitus 109 (24.4)
Hypertension 283 (63.3)
Hyperlipidemia 141 (31.5)
Smoking history 240 (53.7)
History of IHD 182 (40.7)
History of MI 116 (26.0)
Angina pectoris 76 (17.0)
Congestive heart failure 36 (8.0)
Previous PTCA 75 (16.8)
Previous CABG 90 (20.1)
Kidney disease, creatinine 2 mg/dl 13 (2.9)
AAA  abdominal aortic aneurysm; BP  bypass procedure; CABG  coronary
artery bypass graft; CEA  carotid endarterectomy; IHD  ischemic heart disease;
MI  myocardial infarction; PTCA  percutaneous transluminal coronary angio-
plasty.
Table 2. Association of Longest Ischemia Duration With Biochemical Markers of MI
Myocardial Infarction Defined As
Total n
(%)*
Ischemia
>15 min
n (%)†
Ischemia
>30 min
n (%)†
Ischemia
>60 min
n (%)†
Symptoms
Attributable
to MI‡
CK 170 IU and MB 5% 34 (6.7) 17 (50.0%) 14 (41.2) 12 (35.3) 7 (20.5)
CK 170 IU and MB 10% 14 (2.9) 8 (57.1) 7 (50.0) 7 (50.0) 5 (35.7)
cTn-I 0.6 ng/ml and/or cTn-T 0.03 ng/ml 107 (23.9) 34 (31.8) 29 (27.1) 21 (19.6) 19 (17.7)
cTn-I 1.5 ng/ml and/or cTn-T 0.1 ng/ml 41 (8.7) 38 (87.8) 24 (58.3) 19 (46.3) 18 (43.9)
cTn-I 3.1 ng/ml and/or cTn-T 0.2 ng/ml 21 (4.2) 19 (90.5) 17 (81.0) 17 (81.0) 13 (61.9)
*Percent of all 501 vascular operations. †All four biochemical criteria of infarction were significantly associated (p  0.001) with both 30 min and 60 min ischemia duration
using chi-square analysis. ‡Prolonged chest pain, congestive heart failure, or new onset arrhythmia.
CK  creatine kinase; cTn-I  cardiac troponin-I; cTn-T  cardiac troponin-T; IU  international units; MB  MB fraction; MI  myocardial infarction.
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markers of infarction (each time a single marker was
included in the model), the following markers indepen-
dently predicted mortality, in the order of severity: 1)
prolonged ischemia 60 min; 2) CK-MB 10%; 3) cTn-I
3.1 ng/ml and/or cTn-T 0.2 ng/ml; 4) CK-MB 5%;
5) prolonged ischemia 30 min; 6) cTn-I 1.5 ng/ml
and/or cTn-T 0.1 ng/ml; and 7) cTn-I 0.6 ng/ml
and/or cTn-T 0.03 ng/ml (Table 3).
When all postoperative markers of ischemia and infarc-
tion were included with the preoperative predictors in the
multivariate analysis, only the following markers indepen-
dently predicted mortality: 1) CK-MB 10%; 2) postoper-
ative ischemia 60 min; and 3) cTn-I 0.6 ng/ml and/or
cTn-T 0.03 ng/ml (odds ratio  2.77, 2.20, and 1.64, p
 0.043, 0.033, and 0.054, respectively). If only the bio-
chemical markers were included with the preoperative
predictors in the multivariate analysis, both CK-MB 10%
and cTn-I 0.6 ng/ml and/or cTn-T 0.03 ng/ml inde-
pendently predicted mortality (odds ratio  4.21 and 1.96,
p  0.002 and 0.005, respectively). If only the lowest cutoff
levels of CK-MB and cTn were included, both CK-MB
5% and cTn-I 0.6 ng/ml and/or cTn-T 0.03 ng/ml
independently predicted mortality (odds ratio  2.14 and
1.89, p 0.018 and 0.01, respectively). Finally, if the lowest
cutoff levels of CK-MB and cTn were excluded from the
multivariate analysis, both CK-MB 10% and cTn-I 1.5
ng/ml and/or cTn-T 0.1 ng/ml independently predicted
mortality (odds ratio 3.75 and 2.06, p 0.006 and 0.012,
respectively).
In additional analysis, patients who had both CK-MB
5% and cTn-I 0.6 ng/ml and/or cTn-T 0.03 ng/ml
had a 4.19-fold increase in mortality (p  0.001). Similarly,
patients with both CK-MB 10% and cTn-I 1.5 ng/ml
and/or cTn-T 0.1 ng/ml had a 4.04-fold increase in
mortality (p  0.007).
DISCUSSION
The main finding of the present study is that even minor
elevations in cTn or CK-MB during the first three postop-
erative days predict increased risk of long-term mortality
after major vascular surgery. Between 14 (2.9%) and 107
(23.9%) of the patients sustained postoperative MI or minor
myocardial damage, depending on the cutoff levels of the
biochemical marker. Higher levels of biochemical markers,
corresponding to a larger volume of myocardial injury or
infarction, predicted worse survival: CK-MB 10% and
cTn-I 1.5 ng/ml and/or cTn-T 0.1 ng/ml predicted
3.75-fold and 2.06-fold increase in long-term mortality,
independent of the preoperative predictors: patient’s age,
type of vascular surgery, previous MI, and renal failure;
CK-MB5% and cTn-I 0.6 ng/ml and/or cTn-T 0.03
ng/ml independently predicted a 2.15-fold and 1.89-fold
increase in mortality. We have previously shown that
Table 3. Univariate and Multivariate Cox Regression Survival Analyses
Patients Who Died
n (%)
Univariate Analysis Multivariate Analysis
Odds Ratio
[95% CI] p Value
Odds Ratio
[95% CI] p Value
Age 1.03 [1.01–1.05] 0.015 1.056 [1.01–1.09] 0.02
Gender (female) 0.66 [0.38–1.15] 0.14
Type of surgery, compared with CEA 28 (13.3)
Aorta 6 (8.6) 0.61 [0.29–1.49] 0.29 2.39 [0.93–6.13] 0.07
Lower-extremity bypass 47 (28.3) 2.32 [1.45–3.71]  0.001 2.52 [1.53–5.09] 0.008
Diabetes mellitus 33 (30.8) 1.74 [1.13–2.72] 0.017
Hypertension 58 (20.3) 1.29 [0.78–2.15] 0.32
Smoking history 34 (21.0) 0.94 [0.59–1.49] 0.83
Hyperlipidemia 20 (14.1) 0.69 [0.19–4.90] 0.71
Ischemic heart disease 38 (27.3) 2.34 [1.29–4.45] 0.004
Previous myocardial infarction 32 (27.6) 1.80 [1.12–2.76] 0.008 1.88 [1.05–3.37] 0.034
Current angina pectoris 18 (27.7) 1.46 [0.86–2.49] 0.14
Congestive heart failure 15 (41.7) 2.65 [1.50–4.65] 0.001
Previous PTCA 15 (20.0) 1.05 [0.59–1.84] 0.86
Previous CABG 21 (23.3) 1.23 [0.74–2.76] 0.43
Kidney disease, creatinine 2 mg/dl 5 (38.5) 2.52 [1.02–6.23] 0.044 5.04 [1.89–13.43] 0.001
Perioperative infarction defined as
CK 170 IU and MB  5% 14 (41.2) 2.88 [1.62–5.11]  0.001 2.71 [1.48–4.98]* 0.001
CK 170 IU and MB  10% 6 (42.8) 3.40 [1.48–7.81] 0.004 5.31 [2.21–12.78]*  0.001
cTn-I 0.6 ng/ml and/or cTn-T 0.03 ng/ml 37 (34.6) 2.30 [1.49–3.55]  0.001 2.15 [1.35–3.42]* 0.001
cTn-I 1.5 ng/ml and/or cTn-T 0.1 ng/ml 16 (39.0) 2.93 [1.75–4.89]  0.001 2.47 [1.44–4.23]* 0.001
cTn-I 3.1 ng/ml and/or cTn-T 0.2 ng/ml 11 (52.3) 3.41 [1.81–6.43]  0.001 2.93 [1.54–5.69]* 0.001
Longest ischemia duration (15 min) 66 (14.7) 2.15 [1.33–3.48] 0.002
Longest ischemia duration (30 min) 18 (40.9) 3.05 [1.84–5.04]  0.001 2.59 [1.51–4.45]* 0.001
Longest ischemia duration (60 min) 13 (56.5) 4.35 [2.45–7.72]  0.001 3.75 [2.07–6.82]*  0.001
*Each one of the postoperative predictors was analyzed separately with the preoperative predictors in the multivariate analysis.
CABG  coronary artery bypass graft; CEA  carotid endarterectomy; CI  confidence interval; PTCA  percutaneous transluminal coronary angioplasty. Other
abbreviations as in Table 2.
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prolonged, silent ST-depression-type postoperative isch-
emia leads to an elevation in troponin and to overt postop-
erative MI (4). In the present study too, prolonged postop-
erative ischemia and elevated troponin levels were strongly
correlated (Table 2). Prolonged 30 min and 60 min
postoperative ischemia was associated, respectively, with a
2.6-fold and 3.7-fold increase in adjusted long-term mor-
tality (Table 3).
Two previous studies investigated the effect of postoper-
ative cTn measurements on outcome after non-cardiac
Figure 1. Kaplan-Meier survival curves of all patients divided according to their highest postoperative troponin level: Group I—cTn-I  0.6 ng/ml and
cTn-T  0.03 ng/ml; Group II—0.6 ng/ml  cTn-I  1.5 ng/ml and/or 0.03 ng/ml  cTn-T  0.1 ng/ml; Group III—1.5 ng/ml  cTn-I  3.1 ng/ml
and/or 0.1 ng/ml  cTn-T  0.2 ng/ml; Group IV—cTn-I  3.1 ng/ml and/or cTn-T  0.2 ng/ml; Groups II, III, and IV had worse long-term survival
than Group I (p  0.047, 0.007, and 0.001, respectively, by log-rank test). cTn  cardiac troponin.
Figure 2. Kaplan-Meier survival curves of all patients divided according to
their highest postoperative creatine kinase-MB fraction (CK-MB) level:
Group I—CK-MB 5%; Group II—5%  CK-MB 10%; Group
III—CK-MB10%; Groups II and III had worse long-term survival than
Group I (p  0.01 and 0.001, respectively, by log-rank test).
Figure 3. Kaplan-Meier survival curves of all patients divided according to
their longest postoperative ischemia duration: Group I—ischemia duration
15 min; Group II—15 min  ischemia duration  30 min; Group
III—ischemia duration 30 min. Group III had worse long-term survival
than Group I (p  0.008, by log-rank test).
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surgery, and both studies followed their patients for only six
months after surgery. Lopez-Jimenez et al. (19) evaluated
the prognostic significance of postoperative cTn-T on
cardiac complications after non-cardiac surgery. In their
study, troponin-T 0.1 ng/ml correlated with overall car-
diac complications, which included cardiac death, nonfatal
MI, or admission for unstable angina during the six months
of follow-up. Abnormal CK-MB values were not associated
with subsequent complications in that study. Recently, Kim
et al. (20) showed that routine troponin-I measurement on
the first three postoperative days predicted all-cause mor-
tality in the first six months after vascular surgery. Yet, no
comparison was made with the parallel measurements of
CK-MB or ischemia duration. More importantly, 12 (67%)
of the 18 patients who died during follow-up died within
the first eight weeks after surgery, thus limiting the ability of
that study to infer the effect of troponin on long-term
survival. The present study corroborates and expands on
those observations by its in-depth analysis of the biochem-
ical markers as well as perioperative ischemia and by its
longer duration of follow-up after surgery.
Troponin levels and MI. There is still an unresolved
debate as to which cutoff levels of troponin should be used
to define a clinically important MI. The conventional cutoff
values, those obtained by titration of troponin to a popula-
tion of patients with medical diagnosis of MI using receiver
operator characteristic curve analyses, were troponin-I 1.5
and troponin-T0.1 ng/ml for the assays used in our study.
On the other hand, the American College of Cardiology/
European Society of Cardiology task force stated in their
consensus document for the redefinition of MI (14) that,
because cTn are so specific to myocardial necrosis, even
minor increases in troponin levels to greater than the 99th
percentile of normal population, in the setting of docu-
mented myocardial ischemia, should be considered as MI.
However, the level of precision of most troponin assays at
this low range is still inadequate. Therefore, somewhat
higher cutoff levels are suggested based on 10% impreci-
sion or coefficient of variation. These levels of cTn-I 0.6
and cTn-T 0.03 ng/ml for our assays were used in the
present study. Both the conventional cutoff levels, cTn-I
1.5 and/or cTn-T 0.1 ng/ml, by which 8.9% of the
patients were identified as having postoperative MI, and the
lower cutoff levels, cTn-I0.6 and/or cTn-T0.03 ng/ml,
by which 23.9% of the patients had postoperative MI or
minor myocardial damage, predicted long-term survival in
accordance with recent findings in different kinds of patients
with unstable coronary syndromes (21,22).
Troponin versus CK-MB. The CK-MB levels predicted
long-term mortality independent of cTn. Fifteen (3.4%)
patients had CK-MB 5% but troponin-I 0.6 ng/ml and
troponin-T 0.03 ng/ml; 3 (20%) of these 15 patients died
during follow-up. In comparison, 88 (19.6%) patients with
elevated troponin (cTn-I 0.6 ng/ml and/or cTn-T 0.03
ng/ml) had normal postoperative CK-MB (5%); 26
(29.5%) of them died during follow-up. Thus, troponin
alone detected more patients with infarction and increased
risk of mortality than CK-MB alone. It is important to
note, however, that CK-MB 10% was associated with
worse adjusted long-term survival than troponin-I 1.5
ng/ml and/or troponin-T 0.1 (odds ratio  5.31 vs. 2.37,
respectively), and similarly, CK-MB 5% predicted worse
prognosis than the lower cutoff levels of troponin (Table 3).
This observation may be explained by the higher sensitivity
of troponin than CK-MB to even small MI or minimal
necrosis, such that have less impact on prognosis than
CK-MB. Whether CK-MB was more sensitive than tro-
ponin in detecting myocardial necrosis in a minority (3.4%)
of the patients without increase in troponin, or reflected
skeletal muscle injury due to more extensive surgery or
lower-extremity ischemia and therefore worse survival (skel-
etal muscle may contain up to 10% CK-MB [23]), could not
be determined by this study. However, patients with both
elevated CK-MB and troponin had a 4.19-fold increase in
mortality, whereas patients with only one of these markers
had a 2.0- to 2.2-fold increase in mortality.
Clinically evident infarction. Only 25 (5.6%) of the pa-
tients satisfied the conventional clinical definition of MI
according to the World Health Organization, i.e., the
existence of at least two of the three criteria: prolonged chest
pain, elevated CK-MB or cTn, and ischemic ECG changes
(24). However, even in these patients the diagnosis of MI
was not possible unless there was routine postoperative
measurement of biochemical markers and continuous ECG
monitoring, because only 16 (3.6%) of the patients had
prolonged chest pain or congestive heart failure suspicious
of overt MI. Our data corroborate those published by Kim
et al. (20) wherein 12% of the patients had elevated
troponin-I on routine postoperative surveillance, yet only
3% had clinical infarction according to the World Health
Organization definition. Therefore, routine monitoring of
cTn, CK-MB, and silent ischemia in the first postoperative
days may provide important information on both the
short-term and long-term risk of major vascular surgery
patients.
The present study is also significant from the aspect of the
pathophysiology of PMI. Recent studies have emphasized
the prognostic importance of even minor elevations of cTn
in patients with unstable coronary syndromes. Patients
undergoing elective major vascular surgery constitute a
different type of cardiac patients than those with unstable
coronary syndromes. The former often have long-standing,
yet stable CAD, and their postoperative cardiac events are
typically caused by stress-induced, ST-depression-type isch-
emia leading to infarction (4). It has been long debated
whether this type of silent postoperative ischemia and
infarction is as prognostically meaningful as an ACS. In
contrast to the older literature that cited 36% to 70%
in-hospital mortality after PMI (25), current data show that
early mortality after perioperative infarction is less than
10%, similar to that of non-ST-elevation-type infarction in
non-surgical patients (4,19). This study further shows that
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long-term survival after even minor perioperative infarction
is significantly impaired, in line with what occurs after ACS
in non-surgical patients.
Study limitations. Routine biochemical markers were
measured only on the first three postoperative days. There-
fore, MI evolving later than the third postoperative day may
have been missed by our study protocol. However, previous
studies have shown that the majority (80%) of postoper-
ative MI occur on the first two days after surgery (3,4,5,19).
Therefore, although extending the biochemical marker
measurements to the rest of the convalescence period could
possibly identify more patients at increased risk for long-
term mortality, it was not likely to affect the main findings
of our study significantly.
We did not investigate the causes of the long-term
deaths. Although the availability of such data could
strengthen the study, numerous previous studies showed
that the majority of deaths in vascular surgery patients are
cardiac in nature and that close to half of the other
non-cardiac causes of death are cardiovascular (26–29).
Because not all our patients were prospectively followed for
the entire follow-up period, we felt that retrospective
collection of the causes of death might introduce significant
inaccuracy to our data.
Although in the vast majority of postoperative patients
the elevation of cardiac-specific markers is due to ischemic
heart disease, there may be other clinical conditions such as
pulmonary embolism, sepsis and renal failure, that may
cause elevations of these markers and lead to an adverse
prognosis.
Conclusions. Cardiac troponin, CK-MB, and prolonged
postoperative ischemia predict long-term mortality after
major vascular surgery. Troponin and CK-MB have an
independent effect on long-term survival, and the combina-
tion of both is associated with even worse survival. Further
studies are needed to test whether routine measurement of
postoperative cardiac markers is cost-effective and whether
more aggressive diagnostic and treatment strategies for
patients with postoperative MI improve survival.
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